CTLA4 and melanoma: In recent years, immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and ipilimumab, represented by PD-1/PD-L1 (35) and CTLA-4 (36), have significantly improved the long-term survival rate of patients with melanoma and have become an important treatment option, especially in advanced or metastatic cases.